Objective: To confirm the association between exposure to chrysotile asbestos and lung cancer risk and to demonstrate the combined effect of smoking and asbestos exposure.
Methods: A case-control study of 1139 asbestos workers identified 41 male lung cancer cases in 2001; each case was matched by age (±5 years) with five controls. Workers in seven workshops were categorised into high-, medium- and low-exposure subgroups, and conditional logistic regression was applied to estimate the odds ratios for lung cancer risk associated with the different exposure levels. Smoking, age at first exposure, and exposure duration were considered as covariates/confounding factors. A joint effect of asbestos exposure and smoking on lung cancer risk was analysed using a conditional logistical model.
Results: 54% of cases had high exposure and 24% low exposure, while 24% of controls had high exposure and 44% low exposure. Smoking was more common in cases (90%) than in controls (73%). The adjusted OR for lung cancer was 3.66 (95% CI 1.61 to 8.29) for high exposure and was elevated slightly for medium exposure (1.25; 95% CI 0.47 to 3.31). Smoking was related to lung cancer risk (OR 3.33; 95% CI 1.10 to 10.08). In comparison with the low-exposure non-smoking group, the OR for the high-exposure smoking group was 10.39 (1.34 to 82.45), in contrast to 5.23 (0.50 to 54.58) for high-exposure non-smoking workers.
Conclusions: These results confirm the strong association between exposure to chrysotile asbestos and lung cancer risk, and support an interactive effect of asbestos exposure and smoking which is more than additive.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2991074 | PMC |
http://dx.doi.org/10.1136/oem.2009.051615 | DOI Listing |
Mayo Clin Proc
January 2025
Section of Clinical Biochemistry, University of Verona, Verona, Italy.
J Thorac Cardiovasc Surg
January 2025
Department of Thoracic Surgery I, Key Laboratory of Lung Cancer of Yunnan Province, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University, Cancer Center of Yunnan Province, Kunming, China.
Trends Pharmacol Sci
January 2025
Department of Surgery, University of California, San Francisco, San Francisco, CA, USA; Center for Bioengineering and Tissue Regeneration, University of California, San Francisco, San Francisco, CA, USA; UCSF Helen Diller Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA; Department of Radiation Oncology, Eli and Edythe Broad Center for Regeneration Medicine and Stem Cell Research, University of California, San Francisco, San Francisco, CA, USA.
Fibrosis accounts for approximately one-third of disease-related deaths globally. Current therapies fail to cure fibrosis, emphasizing the need to identify new antifibrotic approaches. Fibrosis is defined by the excessive accumulation of extracellular matrix (ECM) and resultant stiffening of tissue stroma.
View Article and Find Full Text PDFClin Lung Cancer
December 2024
Department of Thoracic Surgery, Liverpool Heart and Lung Hospital, Liverpool, UK.
Background: To evaluate the real-world surgical and pathological outcomes following neoadjuvant nivolumab in combination with chemotherapy in a multicentre national cohort of patients.
Methods: Retrospective analysis on consecutive patients treated in three tertiary referral hospitals in UK with neoadjuvant chemotherapy and immunotherapy (nivolumab) for stage II-IIIB nonsmall cell lung cancer (March 2023-May 2024). Surgical and pathological outcomes were assessed.
Clin Lung Cancer
December 2024
Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD.
Objective: To determine the association between concurrent statin use with immune checkpoint inhibitors (ICIs) and lung cancer-specific and overall mortality in patients with nonsmall cell lung cancer (NSCLC).
Materials And Methods: SEER-Medicare was used to conduct a retrospective study of Medicare beneficiaries ≥65 years of age diagnosed with NSCLC between 2007 and 2017 treated with an ICI. Patients were followed from date of first ICI claim until death, 1 month from last ICI claim, or 12/31/2018, whichever came first.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!